Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Anle138b
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Evotec | Quotient Sciences | Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Anle138b is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 08, 2022
Lead Product(s) : Anle138b
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Evotec | Quotient Sciences | Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Anle138b is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 28, 2020
MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson´s Disease
Details : The short-term Phase 1b study with PD patients will be conducted by Quotient Sciences in e clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease (PD).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 23, 2020
Details : Anle138b which was administered in doses of up to 300 mg daily, demonstrated excellent safety and tolerability profiles at all dose levels and reached significantly higher plasma levels in humans than those required for full therapeutic efficacy in anima...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 05, 2020